Piramal Pharma Ltd’s stock reached an intraday low of Rs.134.8 on March 16, 2026, reflecting a significant decline over the past year. The company’s financial performance raises concerns among investors.
The numbers
Piramal Pharma Ltd’s stock touched an intraday low of Rs.134.8 on March 16, 2026, marking a significant downturn for the company. Over the last year, the stock has experienced a decline of 32.81%, raising alarms among investors and market analysts alike.
In the latest quarterly report, Piramal Pharma reported a Profit Before Tax loss of Rs.95.99 crore and a Profit After Tax loss of Rs.95.08 crore. These figures highlight the ongoing financial difficulties faced by the company, which has been rated as a Strong Sell by analysts.
The company’s Earnings per Share (EPS) hit a low of Rs.-1.03, further emphasizing the challenges it is currently navigating. Additionally, Piramal Pharma Ltd carries a high Debt to EBITDA ratio of 3.83 times, which may deter potential investors concerned about the company’s financial health.
Despite these challenges, institutional investors hold a significant stake of 45.35% in Piramal Pharma Ltd, indicating a level of confidence in the company’s long-term prospects. However, the recent performance trends suggest that many investors are re-evaluating their positions.
Piramal Pharma Ltd has been on a losing streak for four consecutive sessions, and the recent stock price movements have only intensified scrutiny from market observers. The combination of financial losses and a declining share price has led to increased caution among potential investors.
As the company navigates these turbulent waters, market analysts will be closely monitoring future earnings reports and any strategic changes that may be implemented to address the current financial situation. Details remain unconfirmed regarding any immediate plans for recovery or restructuring.
In summary, the current state of Piramal Pharma’s share price reflects broader concerns about its financial viability. Investors and analysts alike will be watching closely to see how the company responds to these challenges in the coming months.
